Integrum plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data

MÖLNDAL, Sweden, Nov. 13, 2023 /PRNewswire/ — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has held a pre-submission meeting with the US Food and Drug Administration (FDA) to discuss the regulatory pathway for the use of Integrum’s OPRA™…